2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1744

Regulatory B Cells Supress the Progression of Fatal Autoimmunity in Lupus-Prone Mice
Abstract Number: 2087

Regulatory Effect of the Combination of Methotrexate and 1,25-Dihydroxyvitamin D3 On the Balance of Treg and Th17 in Collagen-Induced Arthritis
Abstract Number: 1185

Regulatory Role of 1, 25 Dihydroxyvitamin D3 in the Pathogenesis of Autoimmune Arthritis
Abstract Number: 1919

Regulatory T Cells in IgG4-Related Disease Patients Presenting with Sclerosing Sialadenitis and Dacryoadenitis
Abstract Number: 600

Regulatory T Cells in Spondyloarthritis (SpA) Animal Model and Modulatory Role of Inducible Costimulator (ICOS)
Abstract Number: 2357

Relapses in Patients with Giant-Cell Arteritis: Prevalence, Characteristics and Associated Clinical Findings in a Prospectively Followed Cohort of 106 Patients
Abstract Number: 1115

Relation Between Hip Dysplasia, Pain, and Osteoarthritis in a Cohort of Patients with Hip Symptoms
Abstract Number: 1977

Relationship Between Baseline Bone Turnover Marker Levels and Bone Mineral Density Changes in Men with Low Bone Mineral Density Receiving Denosumab or Placebo
Abstract Number: 1998

Relationship Between Changes in Bone Mineral Density and Incidence of Fracture with 6 Years of Denosumab Treatment
Abstract Number: 2133

Relationship Between Clinical Response and Radiographic Outcomes in Patients with Moderate Rheumatoid Arthritis
Abstract Number: 1410

Relationship Between Individual Organ Damage and Mortality of Systemic Lupus Erythematosus (SLE): A Prospective Cohort Study of 679 Patients
Abstract Number: 1274

Relationship Between Morning Stiffness Duration and Severity, Pain Intensity, and Measures of Disease Activity in a 12 Week Efficacy Study of a Modified (Delayed-Release) Prednisone Plus Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Abstract Number: 1816

Relationship Between Race, Uric Acid Levels, Urate-Lowering Therapy and Resource Use in Patients with Gout
Abstract Number: 1703

Relationship Between Tobacco Smoking and Radiographic Spinal Progression in Axial Spondyloarthritis: The Role of Inflammatory Activity
Abstract Number: 242

Relationship of Objective to Self-Reported Physical Activity Measures Among Adults in the Osteoarthritis Initiative

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].